Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:33:14.320Z.
Calculation as of: 2026-10-06T21:33:14.320Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a49bf55b95e7accb53c24ef9933cb867312288378507dab28e57e4bc75072383
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$25.22M
Price/FCF Ratio
N/A
TTM Avg
242.89
3Y Avg
242.89
5Y Avg
242.89
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InspireMD, Inc. (NSPR) | $24.60M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.13M | N/A | 118.09 | 118.84 | 145.02 |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.22M | N/A | 242.89 | 242.89 | 242.89 |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.38M | 7.49 | 10.70 | 8.48 | 6.39 |
| Rein Therapeutics Inc. (RNTX)vs › | $23.06M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.68M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $27.03M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | 6.77 | 13.56 | 13.45 | 13.45 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
